Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 1, 1999, Pages 231-235

  Filipski, Elisabeth ^a   Amat, Sophie ^a   Lemaigre, Guy ^a   Vincenti, Marc ^b   Breillout, Fabienne ^b   Lévi, Francis A ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMITOTIC AGENT; NAVELBINE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW NECROSIS; CANCER PATIENT; CANCER SURVIVAL; CIRCADIAN RHYTHM; DOSE RESPONSE; DRUG EFFICACY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; LEUKOPENIA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW; CIRCADIAN RHYTHM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOLOGIC DISEASES; INTESTINES; LEUKEMIA P388; LEUKOCYTE COUNT; MICE; TIME FACTORS; VINBLASTINE;

EID: 0032917963     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Cros S, Wright M, Morimoto M, Lataste H, Couzinier JP and Krikorian A (1989) Experimental antitumor activity of Navelbine. Semin Oncol 16:15-20.
2. Cvitkovic E and Izzo J (1992) The current and future place of vinorelbine in cancer therapy. Drugs 44 (Suppl 4): 36-45.
3. Haus E, Halberg F, Scheving LE, Pauly JE, Cardoso S, Kuhl JFW, Sothern R, Shiotsuka R and Hwang D (1972) Increased tolerance of leukemic mice to arabinosyl cytosine given on schedule adjusted to circadian system. Science (Wash DC) 177:80-82.
4. Hrushesky W (1985) Circadian timing of cancer chemotherapy. Science (Wash DC) 228:73-75.
5. Lévi F (1997) Chronopharmacology of anticancer agents, in Handbook of Experimental Pharmacology (Redfern PH and Lemmer B eds) vol: Physiology and Pharmacology of Biological Rhythms, pp 299-331, Springer-Verlag, Berlin.
6. Lévi F, Zidani R, Misset J-L, for the International Organization for Cancer Chronotherapy (1997) Randomized multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681-686.
7. Lévi F, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R, Cholet P, Garufi C, Itzhaki M, Dogliotti L, Iacobelli S, Adam R, Kunstlinger F, Gastiaburu J, Bismuth H, Jasmin C and Misset J-L (1994) Chronomodulated versus fixed infusion rate delivery of ambulatory chemotherapy with oxaliplatin, 5-fluorouracil and folinic acid in patients with colorectal cancer metastases. A randomized multiinstitutional trial. J Natl Cancer Inst 86:1608-1617.
8. 1 phase arrest and p53 overexpression in mouse bone marrow (BM). Relationship with toxicity circadian rhythm. Proc Am Assoc Cancer Res 39:1138.
9. Mormont MC, Berestka J, Mushiya T, Langevin T, von Roemeling R, Rabatin J, Sothern R and Hrushesky W (1986) Circadian dependency of vinblastine toxicity, in Annual Review of Chronopharmacology (Reinberg A, Smolensky M and Labreque G eds) pp 187-190, Pergamon Press, Oxford.
10. Tampellini M, Filipski E and Lévi F (1995a) Circadian variation of vinorelbine toxicity in mice. Chronobiology Int 12:195-198.
11. Tampellini M, Filipski E, Liu XH, Lemaigre G, Li XM, Vrignaud P, François E, Bissery MC and Lévi F (1998) Docetaxel chronopharmacology in mice. Cancer Res 58:3896-3904.
12. Vendetti JM (1975) Drug evaluation branch program. Report to the screening contractors. Cancer Chemother Rep Part 2:1-4.
13. Zhou X-J and Rahmani R (1992) Preclinical and clinical pharmacology of Vinca alkaloids. Drugs 44 (Suppl 4): 1-16.